Swedish study finds higher renal failure rate for Visipaque than Hexabrix

December 10, 2008 Swedish study finds higher renal failure rate for Visipaque than Hexabrix By James Brice With the introduction of iso-osmolar contrast media, radiologists looked forward to the day when severe adverse reactions to x-ray contrast would be eliminated. That day has yet to come, at least as far as the long-term effects of such agents, according to a large retrospective Swedish study. That research identified a significantly higher rate of renal failure among patients administered iso-osmolar iodixanol (Visipaque) compared with patients who received low-osmolar ioxaglate (Hexabrix). Dr. Per Liss and colleagues from the radiology, physiology, and cardiology departments at the University of Uppsala in Sweden presented their evaluation of 23,224 patients at the 2008 RSNA meeting. They found that 1.7% of patients who received iodixanol developed primary or secondary renal failure within 12 months of administration. The 12-month renal failure rate for patients who received ioxaglate was 0.8%.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC